Disease modifying therapies and infection risks in multiple sclerosis—a decision-making conundrum | Zendy

Kok Pin Yong | Zendy; Ho Jin Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Disease modifying therapies and infection risks in multiple sclerosis—a decision-making conundrum

Author(s) -

Kok Pin Yong,

Ho Jin Kim

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.01.119

Subject(s) - multiple sclerosis , disease , medicine , intensive care medicine , bioinformatics , immunology , biology

Department of Neurology, National Neuroscience Institute, Singapore; Duke-NUS Graduate Medical School, Singapore; Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea Correspondence to: Dr. Ho Jin Kim. Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. Email: hojinkim@ncc.re.kr. Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Jinming Han, MD (Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden). Comment on: Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2019. [Epub ahead of print].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research